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We surveyed pediatric infectious disease physicians through
the Infectious Disease Society of America’s Emerging Infections
Network regarding the diagnosis and management of encephalitis. We identified practice variations, particularly with the use
of new diagnostic modalities and management of autoimmune
encephalitides. These findings may inform the creation of updated management guidelines.
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Encephalitis is a devastating disease, which may produce severe
neurodevelopmental abnormalities and extreme morbidity in
survivors [1]. Unfortunately, a myriad of pathogens are associated with this illness, many of which are difficult to diagnose and
are without effective therapies [2–4]. In addition, noninfectious
causes of encephalitis may have overlapping signs and symptoms
with infectious causes, further complicating attempts at effective

diagnosis [5]. Since the publication of the most recent Infectious
Disease Society of America (IDSA) guidelines addressing encephalitis in 2008 [4], many changes in the diagnosis and epidemiology of pediatric encephalitis have emerged. Multiplex
polymerase chain reaction (PCR) testing [6] and metagenomic
next-generation sequencing (mNGS) [3] of the cerebrospinal fluid
(CSF) have increasingly entered clinical practice. Autochthonous
transmission of tropical neurotropic viral pathogens has arisen in
several US states as well (eg, Chikungunya virus) [7]. Increasingly,
clinicians are appreciating the emerging disease burden caused
by autoimmune encephalitides [8]. These developments have
greatly changed the diagnostic approach for this disease. In an effort to characterize how clinicians are adapting to these changes,
we surveyed pediatric infectious disease physicians via the IDSA’s
Emerging Infections Network (EIN) to ascertain their approach
to several evolving clinical issues related to the management of
encephalitis in children.
METHODS

An 11-question, confidential, web-based survey link was distributed to 370 pediatric infectious disease physician members
of the EIN of the IDSA and remained open between January
29 and February 17, 2020 (Supplementary File). Nonresponders
received 2 reminders approximately 1 week apart. Only responses from providers caring for children with suspected
encephalitis were analyzed. Respondents were characterized
by the region of the country in which they practiced, years of
experience since fellowship, their place of employment, and
their primary hospital type. The survey assessed respondents’
approaches to the use of multiplex PCR and mNGS testing in
the CSF, their likelihood of testing for autochthonous tropical viral pathogens in the United States in a hypothetical scenario, their role and comfort level in evaluating and caring for
children with autoimmune encephalitides, as well as criteria for
initiating immunomodulatory agents in a child with suspected
encephalitis. A Chi-square test was used to compare frequencies (SAS v.9.4).
RESULTS
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Responses were received from 222 of 370 members (60%); the response rate was based only on members who had ever responded
to an EIN survey [9]. Of the 222 respondents, 196 (88%) reported caring for children with suspected encephalitis and form
the basis for the report. Of note, respondents were more likely
than nonrespondents to have fewer than 5 years of pediatric infectious disease experience (25% vs 14%, P = .04). A majority of
respondents worked in an academic medical setting (65%).
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Fifty-six percent of respondents reported that the use of
multiplex PCR testing of CSF was not subject to institutional
restrictions; 20% reported that this testing was not used at their
institution. Multiplex PCR testing of CSF in the initial evaluation of most children with suspected encephalitis was reported
by 110 (56%) of respondents, with 65% of these (71 of the 110
respondents) conducting pathogen-specific testing to confirm
results (Table 1). Sixty respondents (31%) would likely require
diagnoses to be excluded by standard testing (eg, cultures,
herpes simplex virus PCR) prior to the use of a multiplex PCR
assay. Additionally, 25 of these 60 respondents (42%) would
only pursue multiplex PCR testing if a child were not clinically
improving.
CSF mNGS had been used by 47% of providers (Table 2).
Overall, if CSF mNGS were available in a timely and cost-effective manner, 74% of respondents (n = 145) stated that they
would use it only if likely diagnoses were excluded via standard
testing, of whom 64% (93 of these 145 respondents) would only
use mNGS if a child were not improving. Of note, 11% of providers reported being unaware of mNGS of the CSF, 13% were
unsure how best to use the test, and 40% were aware of the test
but had never ordered it. Metagenomic NGS results without
an identified pathogen were interpreted to mean no infection
would be present by only 2% of respondents, while 68% felt the
results would not exclude an infection (Table 2).
For autoimmune encephalitis, 33% of pediatric Infectious
disease physicians were primarily responsible for the diagnostic
evaluation, but only 55% of those surveyed reported feeling
comfortable diagnosing this condition. Pediatric neurology
services were listed as primarily responsible for diagnosis by
84% of respondents (respondents could select multiple services with primary responsibility for the diagnostic evaluation).
Marked variation existed regarding the decision-making used

Table 1. Approach to the Use of Multiplex Polymerase Chain
Reaction Testing in the Cerebrospinal Fluid of Children With Suspected
Encephalitis by 196 Pediatric Infectious Disease Physicians
Diagnostic Approach
Would not use

Number (%) of Respondents
8 (4%)

Would use only if likely diagnoses excluded with standard
testing (eg, culture, HSV PCR)

35 (18%)

Would use only if likely diagnoses excluded with standard
testing AND the child was not improving

25 (13%)

Would use in the initial evaluation of most children with suspected encephalitis, WITH pathogen-specific confirmatory
testing

71 (36%)

Would use in the initial evaluation of most children with
suspected encephalitis, WITHOUT pathogen-specific confirmatory testing

39 (20%)

Not sure
Other approach
Did not answer question
Abbreviations: HSV, herpes simplex virus; PCR, polymerase chain reaction.
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prior to the initiation of immunomodulatory agents in a child
with suspected encephalitis. Negative results from pathogenspecific testing were required by 87% of respondents, and a
request from the neurology and/or rheumatology services was
required by 64%. Defervescence was required by 11% of respondents, normal CSF indices by 23%, and reassuring magnetic resonance imaging of the brain (absence of necrosis and
enhancement and diffusion-weighted abnormalities) by 50%.
Regarding the need for testing for autochthonous tropical
viruses in the United States in a hypothetical pediatric patient
with suspected encephalitis and no travel history, 42% of respondents reported that they would be somewhat likely or very
likely to screen for such infections, 26% were somewhat unlikely
or very unlikely to pursue such testing or reported conditional
requirements for testing, and 18% were uncertain.
DISCUSSION

We found marked variability in the approach to evaluation and
management of children with suspected encephalitis by pediatric infectious disease physicians. The diagnostic approach to
children with encephalitis varied greatly in the ways newer diagnostic modalities, such as mNGS and multiplex PCR testing

Table 2. Approach to the Use of Metagenomic Next-Generation
Sequencing of the Cerebrospinal Fluid in Children With Suspected
Encephalitis by 196 Pediatric Infectious Disease Physicians
Topic
Unaware of mNGS

22 (11%)

Aware of mNGS, never used it

79 (40%)

Used mNGS, never found it useful

37 (19%)

Used mNGS, found it useful in select situations

53 (27%)

Used mNGS, usually find it useful

2 (1%)

Did not answer question

3 (1%)

How mNGS of CSF would be used if available in a timely and cost-effective manner
Would not use

11 (6%)
2 (1%)

7 (4%)

Would use only if likely diagnoses excluded with standard
testing (eg, culture, HSV PCR)

52 (27%)

Would use only if likely diagnoses excluded with standard
testing AND the child was not improving

93 (47%)

Would use as standard test in the initial evaluation of most
children with suspected encephalitis

12 (6%)

Not sure

25 (13%)

Other approach

5 (3%)

Did not answer question

2 (1%)

Interpretation of negative CSF mNGS results in a child with suspected encephalitis
No infection

5 (3%)

Number (%) of Respondents

Prior experience with mNGS

4 (2%)

Infection unlikely, but cannot exclude infection

44 (22%)

Infection less likely, but cannot exclude infection

91 (46%)

Would not change initial suspicion of infection

30 (15%)

Unsure

25 (13%)

Did not answer question

2 (1%)

Abbreviations: mNGS, metagenomic next-generation sequencing; CSF, cerebrospinal fluid; HSV, herpes simplex virus; PCR, polymerase chain reaction.

of CSF, were implemented. Providers reported differences in
multiplex PCR test availability and use, test ordering restrictions, and test interpretation with regard to pathogen-specific
confirmatory testing [10].
Around half of the providers surveyed had used mNGS
testing of CSF, though disagreement existed about the optimal timing and the interpretation of results. In particular,
negative results from mNGS testing were interpreted with
differing levels of confidence to exclude infectious causes.
Due to the transient and, at times, relatively brief presence of
many viral encephalitis pathogens in the CSF (eg, flaviviruses)
[11], mNGS and multiplex PCR testing may be somewhat
limited in utility, and serological testing of the blood and/or
the CSF (or more invasive approaches, such as brain biopsy)
[3] may be needed to augment the diagnostic approach in
such instances [3].
Given the large number of infectious causes of encephalitis
without effective treatments, providers may also not feel obligated to pursue a specific diagnosis with mNGS or multiplex
PCR testing, particularly once treatable and common causes
have been excluded, especially when the child is clinically
improving. Indeed, nearly three-fourths of our respondents reported that they would only use mNGS on CSF in a child with
suspected encephalitis if likely diagnoses were excluded by
standard testing, and nearly two-thirds of those respondents
would additionally only pursue such testing if the child were
not improving. However, the unbiased approach to diagnosis
afforded by mNGS offers the potential to identify novel and
emerging neurotropic pathogens which may otherwise evade
detection [3].
Our survey also highlights not only the important role many
infectious disease physicians play in the evaluation of autoimmune encephalitis but also their relative lack of comfort with
this diagnosis. Though not a primary infectious process, these
survey findings highlight the need for enhanced training, updated directives in clinical guidelines, and a clearer delineation of duties amongst pediatric providers caring for children
with autoimmune encephalitides. Similarly, the criteria used to
guide the initiation of immunomodulatory agents in children
with suspected encephalitis varied tremendously. Many of the
respondents would require the absence of findings that could
be concerning for infectious encephalitis (eg, fever, abnormal
brain magnetic resonance imaging (MRI), and abnormal CSF
indices) but are also common in the autoimmune encephalitides
and, therefore, may delay definitive therapy in these cases.[8]
Clinical management guidelines for encephalitis from the
IDSA were last published in 2008 [4], though the International
Encephalitis Consortium has published diagnostic guidance
in a consensus statement from 2013 [12]. Guidelines should
be updated to address the uncertainties we identified with the
use of mNGS, multiplex PCR testing, testing for autochthonous
tropical viruses, and autoimmune encephalitis evaluation and

management. Incorporating these new technologic advances
and emerging clinical challenges into updated guidelines,
guided by current research, may help optimize and standardize
the approach of pediatric infectious disease physicians to this
challenging patient population.
CONCLUSIONS

Tremendous variability exists regarding the use of novel diagnostic tools in children with suspected encephalitis and the
management of emerging encephalitides, such as autoimmune
encephalitis, by pediatric infectious disease physicians. Revised
and updated clinical guidelines addressing these gaps in knowledge may help standardize care of children with suspected
encephalitis.
Supplementary Data
Supplementary materials are available at the Journal of the Pediatric
Infectious Diseases Society online.
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